Nuedexta is owned by Avanir Pharms.
Nuedexta contains Dextromethorphan Hydrobromide; Quinidine Sulfate.
Nuedexta has a total of 2 drug patents out of which 0 drug patents have expired.
Nuedexta was authorised for market use on 29 October, 2010.
Nuedexta is available in capsule;oral dosage forms.
Nuedexta can be used as treatment of pseudobulbar affect.
The generics of Nuedexta are possible to be released after 13 August, 2026.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US8227484||AVANIR PHARMS||Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders|| |
(5 months from now)
|US7659282||AVANIR PHARMS||Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders|| |
(3 years from now)
Market Authorisation Date: 29 October, 2010
Treatment: Treatment of pseudobulbar affect
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic